| Study summary: |
|
A randomized, double-blind, placebo-controlled, phase 3 study to evaluate the efficacy, safety, and tolerability of study medication in the treatment of patients with diarrhea-predominant irritable bowel syndrome. |
| Qualified participants must: |
|
• Be 18-80 years of agel
Have a diagnosis of diarrhea predominant IBS
•
Be willing to comply with study procedures and daily diary call
•
Not have a history of inflammatory GI disorder (ex. Crohns disease, ulcerative colitis) or celiac disease
•
Not have had abdominal surgery within 3 months, or major gastric, hepatic, pancreatic or intestinal surgery (appendectomy, hemorrhoid surgery or polyp removal if greater than 3 months is allowed)
•
Not have had an MI, Stroke or congestive heart failure within 6 months or a history of malignant cancer with 5 years (basal cell, skin cancer or cervical cancer if treated are allowed)
•
Not have a history of alcohol abuse or binge drinking (recovered alcoholics who have not consumed alcohol in over 5 years are allowed)
•
Not have had a history of microbiologically documented lower GI infection within 3 months
|
| Participants may receive: |
|
Study medication, study related medical care and laboratory studies at no cost and compensation for time and travel is available. |
| Study is available at: |
|
Advanced Clinical Research Center of Houston
Dr. Roger C. Willette/Medical Director
1051 Pineloch Drive, Suite 600
Houston, Texas 77062
View Clinic Location
If you meet the above criteria and live within 75 miles of this clinic please enter your information below and click "I Am Interested In This Study" to be contacted by the study coordinator.
or
Click "View Contact Phone Number" to get the clinic's phone number.
|